Home / Centerstage / 2014 / august / Week 3 /
Swiss drugmaker Roche agrees to acquire American drugmaker InterMune for $8.3 billion, aiming to expand its presence in the treatment of rare and incurable diseases. This move allows Roche to diversify its portfolio beyond cancer drugs and capitalize on InterMune's expertise in respiratory treatments. Roche's previous efforts in non-cancer drugs have seen mixed results, prompting this strategic acquisition.
Saturday, 23 August, 2014